FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ZNF415-EIF3H

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ZNF415-EIF3H
FusionPDB ID: 102023
FusionGDB2.0 ID: 102023
HgeneTgene
Gene symbol

ZNF415

EIF3H

Gene ID

55786

8667

Gene namezinc finger protein 415eukaryotic translation initiation factor 3 subunit H
SynonymsPact|ZfLpEIF3S3|eIF3-gamma|eIF3-p40
Cytomap

19q13.42

8q23.3-q24.11

Type of geneprotein-codingprotein-coding
Descriptionzinc finger protein 415eukaryotic translation initiation factor 3 subunit HeIF-3-gammaeIF3 p40 subuniteukaryotic translation initiation factor 3 subunit 3eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)eukaryotic translation initiation factor 3, subunit 3
Modification date2020031320200313
UniProtAcc.

O15372

Main function of 5'-partner protein: FUNCTION: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). {ECO:0000255|HAMAP-Rule:MF_03007, ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815}.
Ensembl transtripts involved in fusion geneENST idsENST00000440291, ENST00000448501, 
ENST00000455735, ENST00000595193, 
ENST00000594011, ENST00000599261, 
ENST00000243643, ENST00000421033, 
ENST00000500065, ENST00000595813, 
ENST00000596683, ENST00000597503, 
ENST00000597748, ENST00000600574, 
ENST00000601215, ENST00000601493, 
ENST00000276682, ENST00000521861, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 3=2720 X 15 X 12=3600
# samples 332
** MAII scorelog2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(32/3600*10)=-3.49185309632968
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ZNF415 [Title/Abstract] AND EIF3H [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ZNF415 [Title/Abstract] AND EIF3H [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ZNF415(53618957)-EIF3H(117671219), # samples:2
Anticipated loss of major functional domain due to fusion event.ZNF415-EIF3H seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ZNF415-EIF3H seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ZNF415-EIF3H seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
ZNF415-EIF3H seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
ZNF415-EIF3H seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneEIF3H

GO:0006413

translational initiation

17581632



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:53618957/chr8:117671219)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ZNF415 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across EIF3H (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000594011ZNF415chr1953618957-ENST00000521861EIF3Hchr8117671219-4149503611272403
ENST00000594011ZNF415chr1953618957-ENST00000276682EIF3Hchr8117671219-1446503611272403
ENST00000599261ZNF415chr1953618957-ENST00000521861EIF3Hchr8117671219-41174712271240337
ENST00000599261ZNF415chr1953618957-ENST00000276682EIF3Hchr8117671219-14144712271240337

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000594011ENST00000521861ZNF415chr1953618957-EIF3Hchr8117671219-0.0002492390.9997508
ENST00000594011ENST00000276682ZNF415chr1953618957-EIF3Hchr8117671219-0.0009144610.99908555
ENST00000599261ENST00000521861ZNF415chr1953618957-EIF3Hchr8117671219-0.0002392730.9997607
ENST00000599261ENST00000276682ZNF415chr1953618957-EIF3Hchr8117671219-0.000868330.99913174

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ZNF415-EIF3H

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ZNF415chr1953618957EIF3Hchr811767121947181KPKGWEWIKGVKTVQYQMEMMRSLRH
ZNF415chr1953618957EIF3Hchr8117671219503147KPKGWEWIKGVKTVQYQMEMMRSLRH

Top

Potential FusionNeoAntigen Information of ZNF415-EIF3H in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ZNF415-EIF3H_53618957_117671219.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:16KTVQYQMEM0.99490.80861120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:17KTVQYQMEM0.99470.89671120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B58:02KTVQYQMEM0.99240.96441120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B58:01KTVQYQMEM0.99230.95541120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B57:03KTVQYQMEM0.98880.97621120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A32:13KTVQYQMEM0.87660.9481120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A30:08KTVQYQMEM0.85240.68861120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:03IKGVKTVQY0.37950.5384716
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:01WIKGVKTVQY0.99970.8107616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:02WIKGVKTVQY0.96860.8827616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A74:09KTVQYQMEMMR0.97940.82721122
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A74:11KTVQYQMEMMR0.97940.82721122
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A74:03KTVQYQMEMMR0.97940.82721122
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A31:06KTVQYQMEMMR0.97080.5511122
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C15:04KTVQYQMEM0.99790.85641120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C15:06KTVQYQMEM0.99740.85191120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:07KTVQYQMEM0.99690.95311120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C04:06KTVQYQMEM0.99290.9471120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:19KTVQYQMEM0.99270.97711120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:08KTVQYQMEM0.99170.86561120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:14KTVQYQMEM0.88630.97131120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C12:04KTVQYQMEM0.76410.9931120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C06:03KTVQYQMEM0.76310.99141120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C02:06KTVQYQMEM0.60630.92181120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A31:01KTVQYQMEMMR0.98010.79181122
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C15:09KTVQYQMEM0.99790.85641120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C15:05KTVQYQMEM0.9970.88641120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C15:02KTVQYQMEM0.99630.78221120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B57:04KTVQYQMEM0.99620.67351120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B58:06KTVQYQMEM0.99560.9211120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B57:02KTVQYQMEM0.99110.88321120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:04KTVQYQMEM0.98150.98561120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:03KTVQYQMEM0.98150.98561120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:17KTVQYQMEM0.98050.96891120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A32:01KTVQYQMEM0.97950.92891120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:02KTVQYQMEM0.97280.97371120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C03:05KTVQYQMEM0.96830.91961120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C16:02KTVQYQMEM0.94850.99121120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C16:04KTVQYQMEM0.86060.98011120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C16:01KTVQYQMEM0.83870.97861120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C12:03KTVQYQMEM0.78510.98251120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C02:10KTVQYQMEM0.55930.9541120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C02:02KTVQYQMEM0.55930.9541120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-C17:01KTVQYQMEM0.43090.96381120
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B48:02IKGVKTVQY0.24040.7808716
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:53IKGVKTVQY0.11970.7219716
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:54IKGVKTVQY0.05050.6745716
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:34WIKGVKTVQY0.99970.8107616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:33WIKGVKTVQY0.99970.8107616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:125WIKGVKTVQY0.99970.8107616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:135WIKGVKTVQY0.99970.8377616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:50WIKGVKTVQY0.99950.8551616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-B15:35WIKGVKTVQY0.99950.7921616
ZNF415-EIF3Hchr1953618957chr8117671219503HLA-A74:01KTVQYQMEMMR0.97940.82721122

Top

Potential FusionNeoAntigen Information of ZNF415-EIF3H in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ZNF415-EIF3H_53618957_117671219.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0101PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0101KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0103PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0103KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0105PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0105KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0107PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0107KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0109PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0109KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0111PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0111KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0113PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0113KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0115PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0115KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0117PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0117KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0119PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0119KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0121PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0121KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0125PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0125KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0127PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0127KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0129PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0129KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0131PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-0131KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1201WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1201GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1201EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1203WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1203GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1205WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1205GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1205EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1206WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1206GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1206EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1207WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1207GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1207EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1208WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1208GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1208EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1210WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1210GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1210EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1211WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1211GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1211EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1212WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1212GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1212EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1212KGWEWIKGVKTVQYQ217
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1213WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1213GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1213EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1214WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1214GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1214EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1215WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1215GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1215EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1217WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1217GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1217EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1218WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1218GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1218EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1219WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1220WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1221WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1221GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1221EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1223WEWIKGVKTVQYQME419
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1223GWEWIKGVKTVQYQM318
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1223EWIKGVKTVQYQMEM520
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1601PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1601KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1603PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1603KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1604PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1604KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1608PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1608KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1609PKGWEWIKGVKTVQY116
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1609KPKGWEWIKGVKTVQ015
ZNF415-EIF3Hchr1953618957chr8117671219503DRB1-1610PKGWEWIKGVKTVQY116

Top

Fusion breakpoint peptide structures of ZNF415-EIF3H

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10477WIKGVKTVQYQMEMZNF415EIF3Hchr1953618957chr8117671219503

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ZNF415-EIF3H

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10477WIKGVKTVQYQMEM-6.01316-6.12656
HLA-B14:023BVN10477WIKGVKTVQYQMEM-3.92858-4.96388
HLA-B52:013W3910477WIKGVKTVQYQMEM-5.92102-6.95632
HLA-B52:013W3910477WIKGVKTVQYQMEM-4.84472-4.95812
HLA-A24:025HGA10477WIKGVKTVQYQMEM-8.26357-9.29887
HLA-A24:025HGA10477WIKGVKTVQYQMEM-7.03366-7.14706
HLA-B44:053DX810477WIKGVKTVQYQMEM-6.13971-6.25311
HLA-B44:053DX810477WIKGVKTVQYQMEM-5.20728-6.24258
HLA-A02:016TDR10477WIKGVKTVQYQMEM-5.28864-5.40204

Top

Vaccine Design for the FusionNeoAntigens of ZNF415-EIF3H

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ZNF415-EIF3Hchr1953618957chr81176712191120KTVQYQMEMAAACAGTCCAATATCAGATGGAAATGA
ZNF415-EIF3Hchr1953618957chr81176712191122KTVQYQMEMMRAAACAGTCCAATATCAGATGGAAATGATGCGGA
ZNF415-EIF3Hchr1953618957chr8117671219616WIKGVKTVQYGGATCAAAGGTGTGAAAACAGTCCAATATC
ZNF415-EIF3Hchr1953618957chr8117671219716IKGVKTVQYTCAAAGGTGTGAAAACAGTCCAATATC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ZNF415-EIF3Hchr1953618957chr8117671219015KPKGWEWIKGVKTVQAACCAAAAGGGTGGGAATGGATCAAAGGTGTGAAAACAGTCCAAT
ZNF415-EIF3Hchr1953618957chr8117671219116PKGWEWIKGVKTVQYCAAAAGGGTGGGAATGGATCAAAGGTGTGAAAACAGTCCAATATC
ZNF415-EIF3Hchr1953618957chr8117671219217KGWEWIKGVKTVQYQAAGGGTGGGAATGGATCAAAGGTGTGAAAACAGTCCAATATCAGA
ZNF415-EIF3Hchr1953618957chr8117671219318GWEWIKGVKTVQYQMGGTGGGAATGGATCAAAGGTGTGAAAACAGTCCAATATCAGATGG
ZNF415-EIF3Hchr1953618957chr8117671219419WEWIKGVKTVQYQMEGGGAATGGATCAAAGGTGTGAAAACAGTCCAATATCAGATGGAAA
ZNF415-EIF3Hchr1953618957chr8117671219520EWIKGVKTVQYQMEMAATGGATCAAAGGTGTGAAAACAGTCCAATATCAGATGGAAATGA

Top

Information of the samples that have these potential fusion neoantigens of ZNF415-EIF3H

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAZNF415-EIF3Hchr1953618957ENST00000594011chr8117671219ENST00000276682TCGA-AC-A5XU-01A

Top

Potential target of CAR-T therapy development for ZNF415-EIF3H

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ZNF415-EIF3H

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ZNF415-EIF3H

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource